Literature DB >> 8662133

Potential strategies for inflammatory mediator manipulation: retrospect and prospect.

C J Fisher1, Y Zheng.   

Abstract

Sepsis syndrome and septic shock remain significant causes of morbidity and mortality. To date, clinical trials of novel agents to treat sepsis have failed to demonstrate clinical efficacy despite considerable animal data to suggest a positive therapeutic benefit. This article reviews the recent major clinical trials on sepsis and discusses the hypotheses on which these therapies are based and the critical issues associated with clinical sepsis. Recommendations for future clinical trials on sepsis are made.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8662133     DOI: 10.1007/s002689900070

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  5 in total

1.  Bovine intestinal alkaline phosphatase attenuates the inflammatory response in secondary peritonitis in mice.

Authors:  Suzanne Q van Veen; Arlène K van Vliet; Marty Wulferink; Ruud Brands; Marja A Boermeester; Thomas M van Gulik
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

Review 2.  Scorpion venom and the inflammatory response.

Authors:  Vera L Petricevich
Journal:  Mediators Inflamm       Date:  2010-03-14       Impact factor: 4.711

3.  Effects of interleukin-1alpha administration on intestinal ischemia and reperfusion injury, mucosal permeability, and bacterial translocation in burn and sepsis.

Authors:  Tamer Tadros; Daniel L Traber; John P Heggers; David N Herndon
Journal:  Ann Surg       Date:  2003-01       Impact factor: 12.969

4.  Mitogen-activated protein kinases in the intensive care unit: prognostic potential.

Authors:  Matthew R Rosengart; Avery B Nathens; Saman Arbabi; Margaret J Neff; Iris Garcia; Thomas R Martin; Ronald V Maier
Journal:  Ann Surg       Date:  2003-01       Impact factor: 12.969

5.  Multi-drug strategies are necessary to inhibit the synergistic mechanism causing tissue damage and organ failure in post infectious sequelae.

Authors:  I Ginsburg
Journal:  Inflammopharmacology       Date:  1999       Impact factor: 5.093

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.